000931726 000__ 03581cam\a2200457Ia\4500
000931726 001__ 931726
000931726 005__ 20230306151658.0
000931726 006__ m\\\\\o\\d\\\\\\\\
000931726 007__ cr\un\nnnunnun
000931726 008__ 200425s2020\\\\sz\\\\\\o\\\\\001\0\eng\d
000931726 019__ $$a1152545981$$a1153059957$$a1153159655$$a1153951446$$a1154483738
000931726 020__ $$a9783030426675$$q(electronic book)
000931726 020__ $$a303042667X$$q(electronic book)
000931726 020__ $$z9783030426668
000931726 020__ $$z3030426661
000931726 0247_ $$a10.1007/978-3-030-42
000931726 035__ $$aSP(OCoLC)on1152060813
000931726 035__ $$aSP(OCoLC)1152060813$$z(OCoLC)1152545981$$z(OCoLC)1153059957$$z(OCoLC)1153159655$$z(OCoLC)1153951446$$z(OCoLC)1154483738
000931726 040__ $$aEBLCP$$beng$$cEBLCP$$dGW5XE$$dLQU$$dEBLCP$$dYDX
000931726 049__ $$aISEA
000931726 050_4 $$aRM301.63
000931726 08204 $$a615.1/9$$223
000931726 24500 $$aReviews on new drug targets in age-related disorders /$$cPaul C. Guest, editor.
000931726 260__ $$aCham :$$bSpringer,$$c2020.
000931726 300__ $$a1 online resource (343 pages).
000931726 336__ $$atext$$btxt$$2rdacontent
000931726 337__ $$acomputer$$bc$$2rdamedia
000931726 338__ $$aonline resource$$bcr$$2rdacarrier
000931726 4901_ $$aAdvances in experimental medicine and biology, oteomics, metabolomics, interactomics and systems biology
000931726 500__ $$aIncludes index.
000931726 506__ $$aAccess limited to authorized users.
000931726 520__ $$aAging is an inevitable part of life and is becoming a worldwide social, economic and health problem. This is mainly due to the fact that the increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders, such as type II diabetes mellitus, cardiovascular disorders, sarcopenia, and neurodegenerative conditions. New therapeutic approaches are still needed to decrease or slow the effects of such diseases. Advances in -omic technologies, such as genomics, transcriptomics, proteomics and metabolomics, have significantly advanced our understanding of disease in multiple medical areas, as the analysis of multiple molecular networks has simultaneously provided a more integrated view of disease pathways. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan. In turn, this will lead to new therapeutic strategies as well as drug development projects by the pharmaceutical industry. This book presents a series of reviews describing studies that have resulted in identification of new potential drug targets for age-related disorders. Much of this information has come from -omic comparisons of healthy and disease states or from testing the effects of new therapeutic approaches. Authored by experts from around the globe, each chapter is presented in the context of specific chronic diseases or therapeutic strategies. This book is designed for researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians and stakeholders in major drug companies.
000931726 588__ $$aDescription based on print version record.
000931726 650_0 $$aDrug targeting.
000931726 7001_ $$aGuest, Paul C.
000931726 77608 $$iPrint version:$$aGuest, Paul C.$$tReviews on New Drug Targets in Age-Related Disorders$$dCham : Springer International Publishing AG,c2020$$z9783030426668
000931726 830_0 $$aAdvances in experimental medicine and biology.$$pProteomics, metabolomics, interactomics and systems biology.
000931726 852__ $$bebk
000931726 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-42667-5$$zOnline Access$$91397441.1
000931726 909CO $$ooai:library.usi.edu:931726$$pGLOBAL_SET
000931726 980__ $$aEBOOK
000931726 980__ $$aBIB
000931726 982__ $$aEbook
000931726 983__ $$aOnline
000931726 994__ $$a92$$bISE